This suggests that passive immunization with tau antibodies is really a practical therapeutic focus on and which the CSF volume of p-tau262/356 or from the microtubule binding domain (MTBD) can serve as a handy biomarker of tau pathology to observe tau therapeutics in scientific trials.They demonstrated this partnership with both equally pathologic